Evidence map›Paper›PMID 39849174›Full record

SynthesisJournal of neurology2025

Cancer in multiple sclerosis patients following prolonged exposure to disease-modifying therapies (DMTs): a systematic review and meta-analysis.

Vasileios Giannopapas, Vassiliki Smyrni, Dimitrios K Kitsos, Maria Ioanna Stefanou, Aikaterini Theodorou, John S Tzartos, Georgios Tsivgoulis, Sotirios Giannopoulos

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Opioid Signaling in Multiple Sclerosis: Emerging Targets for Repair.International journal of molecular sciences · 2026
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vasileios GiannopapasSecond Department of Neurology, Attikon University Hospital, National & Kapodistrian University of Athens, Athens, Greece.
Vassiliki SmyrniSecond Department of Neurology, Attikon University Hospital, National & Kapodistrian University of Athens, Athens, Greece.
Dimitrios K KitsosSecond Department of Neurology, Attikon University Hospital, National & Kapodistrian University of Athens, Athens, Greece.
Maria Ioanna StefanouSecond Department of Neurology, Attikon University Hospital, National & Kapodistrian University of Athens, Athens, Greece.
Aikaterini TheodorouSecond Department of Neurology, Attikon University Hospital, National & Kapodistrian University of Athens, Athens, Greece.
John S TzartosSecond Department of Neurology, Attikon University Hospital, National & Kapodistrian University of Athens, Athens, Greece.
Georgios TsivgoulisSecond Department of Neurology, Attikon University Hospital, National & Kapodistrian University of Athens, Athens, Greece.
Sotirios GiannopoulosSecond Department of Neurology, Attikon University Hospital, National & Kapodistrian University of Athens, Athens, Greece. sgiannop@uoi.gr.ORCID http://orcid.org/0000-0001-7443-5179

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe current literature on the prevalence and potential association between disease-modifying therapies (DMTs) and cancer risk in the MS population has yielded mixed findings.

methodsThis study aimed to estimate cancer prevalence and cancer risk in patients with MS (PwMS) under prolonged DMT exposure. Database search include: MEDLINE PUBMED, SCOPUS, and Google Scholar.

resultsA total of 13 studies involving 333,779 PwMS were included, reporting cancer events over periods ranging from 6 to 32 years. The aggregated pooled prevalence of cancer events in MS patients receiving disease-modifying therapies (DMTs) was 3.8% (95% CI 2.6, 5.2%), with substantial heterogeneity (I

conclusionThis study reports a 3.8% pooled prevalence of cancer in PwMS receiving DMTs. The findings of this study suggest that DMTs alone do not increase cancer risk in PwMS. Breast cancer and basal cell carcinoma had the highest prevalence among the different types of cancer.

Indexed as

Multiple SclerosisNeoplasmsHumansAutoimmune diseasesCancerDisease-modifying therapiesMalignancyMultiple sclerosis

Identifiers

PMID39849174
PMCPMC11757934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.